DOCSLIB.ORG

Preconception Genetic Carrier Screen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preconception Genetic Carrier Screen Diseases Tested – Preconception Genetic Carrier Screen DISEASE CODE DISEASE CODE 17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY HSD17B3 ATELOSTEOGENESIS, TYPE II SLC26A2 3-@METHYLGLUTACONIC ACIDURIA, TYPE III OPA3 a-THALASSEMIA/MENTAL RETARDATION SYNDROME,NONDELETION TYPE, X-LINKED ATRX 3-BETA-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY TYPE II HSD3B2 ATYPICAL MYCOBACTERIOSIS, FAMILIAL IFNGR1 3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY HMGCL ATYPICAL MYCOBACTERIOSIS, FAMILIAL IFNGR2 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY HADH ATYPICAL MYCOBACTERIOSIS, FAMILIAL IKBKG 3-METHYLGLUTACONIC ACIDURIA, TYPE I AUH ATYPICAL MYCOBACTERIOSIS, FAMILIAL IL12B 3-METHYLGLUTACONIC ACIDURIA, TYPE V DNAJC19 ATYPICAL MYCOBACTERIOSIS, FAMILIAL IL12RB1 ABCD SYNDROME EDNRB ATYPICAL MYCOBACTERIOSIS, FAMILIAL STAT1 ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME AAAS ATYPICAL MYCOBACTERIOSIS, FAMILIAL TYK2 ACHONDROGENESIS, TYPE IB ACG1B SLC26A2 AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE I AIRE ACYL-CoA DEHYDROGENASE, LONG-CHAIN, DEFICIENCY OF ACADL Autosomal mental retardation NSUN2 ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, ACADM Autosomal mental retardation ST3GAL3 ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, ACADVL Autosomal mental retardation CDG 1Q SRD5A3 ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY CYP21A2 BARTH SYNDROME TAZ ADRENOLEUKODYSTROPHY ABCD1 BARTTER SYNDROME, ANTENATAL, TYPE 1 SLC12A1 ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM PEX1 BARTTER SYNDROME, ANTENATAL, TYPE 2 KCNJ1 ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM | PEX10 BETA-HYDROXYISOBUTYRYL CoA DEACYLASE, DEFICIENCY OF HIBCH ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM | PEX13 BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4 AMACR ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM | PEX26 BIOTINIDASE DEFICIENCY BTD ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM | PEX5 BLOOM SYNDROME BLM AGAMMAGLOBULINEMIA, X-LINKED BTK BRANCHED-CHAIN KETO ACID DEHYDROGENASE E1, BETA POLYPEPTIDE BCKDHB AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY ACCPN SLC12A6 BRITTLE CORNEA SYNDROME (Ehlers-Danlos syndrome type VIB) ZNF469 AICARDI-GOUTIERES SYNDROME 1 TREX1 CANAVAN DISEASE ASPA AICARDI-GOUTIERES SYNDROME 2 RNASEH2B CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO CPS1 AICARDI-GOUTIERES SYNDROME 3 RNASEH2C CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE SCO2 AICARDI-GOUTIERES SYNDROME 4 RNASEH2A CARDIOMYOPATHY, DILATED, 3A TAZ AICARDI-GOUTIERES SYNDROME 5 SAMDH1 CARNITINE DEFICIENCY, SYSTEMIC PRIMARY SLC22A5 ALLAN-HERNDON-DUDLEY SYNDROME AHDS SLC16A2 CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY CPT1A ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC POLG CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE CPT2 CIRRHOSIS CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET CPT2 ALPHA THALASSEMIA HBA1 CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL CPT2 ALPHA-METHYLACETOACETIC ACIDURIA ACAT1 CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY SLC25A20 ALPORT SYNDROME, AUTOSOMAL RECESSIVE COL4A3 CARPENTER SYNDROME RAB23 ALPORT SYNDROME, AUTOSOMAL RECESSIVE COL4A4 CARTILAGE-HAIR HYPOPLASIA RMRP ALPORT SYNDROME, X-LINKED Col4A5 CEREBELLAR HYPOPLASIA AND MENTAL RETARDATION WITH OR WITHOUT VLDLR ALSTROM SYNDROME ALMS1 QUADRUPEDAL AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL MPL CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR SNAP29 KERATODERMA AMISH INFANTILE EPILEPSY SYNDROME ST3GAL5 CEREBROOCULOFACIOSKELETAL SYNDROME 1 ERCC6 ANAUXETIC DYSPLASIA RMRP CEREBROTENDINOUS XANTHOMATOSIS CYP27A1 ANHYDROTIC ECTODERMAL DYSPLASIA, IMMUNODEFICIENCY, OSTEOPETROSIS, IKBKG LYMPHEDEMA OLEDAID CEROID LIPOFUSCINOSIS, NEURONAL, 10 CTSD ANTIBODY DEFICIENCY DUE TO ICOS DEFECT ICOS CEROID LIPOFUSCINOSIS, NEURONAL, 6 CLN6 ANTLEY-BIXLER SYNDROME POR CEROID LIPOFUSCINOSIS, NEURONAL, 7 MFSD8 ARGININOSUCCINIC ACIDURIA ASL CEROID LIPOFUSCINOSIS, NEURONAL, 8 CLN8 AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY DDC CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT CLN8 ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY ENPP1 CHARCOT-MARIE-TOOTH DISEASE TYPE 4A GDAP1 ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS VPS33B CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H FGD4 ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 2 VIPAR CHEDIAK HIGASHI SYNDROME LYST ARTS SYNDROME PRPS1 CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC ABCB4 ASPHYXIATING THORACIC DYSTROPHY 2 IFT80 CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 1 ATP8B1 ASPHYXIATING THORACIC DYSTROPHY 3 DYNC2H1 CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2 ABCB11 ATAXIA, EARLY-ONSET, WITH oculomotor apraxia AND HYPOALBUMINEMIA APTX CHONDRODYSPLASIA, BLOMSTRAND TYPE PTH1R ATAXIA-TELANGIECTASIA ATM CITRULLINEMIA, CLASSIC ASS1 Diseases Tested – Preconception Genetic Carrier Screen DISEASE CODE DISEASE CODE COCKAYNE SYNDROME TYPE B ERCC6 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If MPDU1 COCKAYNE SYNDROME, TYPE A ERCC8 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih ALG8 COENZYME Q10 DEFICIENCY PDSS2 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iie COG7 COENZYME Q10 DEFICIENCY APTX CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iif SLC35A1 COENZYME Q10 DEFICIENCY CABC1 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij DPAGT1 COENZYME Q10 DEFICIENCY COQ2 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik ALG1 COENZYME Q10 DEFICIENCY COQ9 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il ALG9 COENZYME Q10 DEFICIENCY PDSS1 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In RFT1 COFFIN-LOWRY SYNDROME CLS RPS6KA3 CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS SLC4A11 COHEN SYNDROME VPS13B CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA ARX COMBINED IMMUNODEFICIENCY, X-LINKED IL2RG CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED L1CAM COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1 GFM1 CORTISOL 11-BETA-KETOREDUCTASE DEFICIENCY HSD11B2 COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2 MRPS16 CRANIOFRONTONASAL SYNDROME EFNB1 COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3 TSFM CREATINE DEFICIENCY SYNDROME, X-LINKED SLC6A8 COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4 TUFM CRISPONI SYNDROME CRLF1 COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5 MRPS22 CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE I EFEMP2 COMBINED SAPOSIN DEFICIENCY PSAP CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE I FBLN5 Complex I Deficiency NDUFA7 CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE II ATP6V0A2 Complex I Deficiency NDUFA1 CYSTIC FIBROSIS CFTR Complex I Deficiency NDUFAF2 CYSTINOSIS, ADULT NONNEPHROPATHIC CTNS Complex I Deficiency NDUFAF4 CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE CTNS Complex I Deficiency NDUFS3 CYSTINOSIS, NEPHROPATHIC CTNS Complex I Deficiency NDUFS4 D-BIFUNCTIONAL PROTEIN DEFICIENCY HSD17B4 Complex I Deficiency NDUFS5 DE SANCTIS-CACCHIONE SYNDROME ERCC6 Complex I Deficiency NDUFS6 DE SANCTIS-CACCHIONE SYNDROME XPA Complex I Deficiency NDUFS7 DEFICIENCY OF ACYL-CoA DEHYDROGENASE FAMILY MEMBER 9 ACAD9 Complex I Deficiency NDUFS8 DEFICIENCY OF INTERLEUKIN 1 RECEPTOR ANTAGONIST IL1RN Complex I Deficiency NDUFV1 DENT DISEASE 1 CLCN5 Complex IV deficiency COX10 DESMOSTEROLOSIS DHCR24 Complex IV deficiency COX15 DIARRHEA 4, MALABSORPTIVE, CONGENITAL NEUROG3 Complex IV deficiency COX6B1 DIASTROPHIC DYSPLASIA SLC26A2 Complex IV deficiency FASTKD2 DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY DLD Complex IV deficiency sco1 DIHYDROPYRIMIDINE DEHYDROGENASE DPYD Complex IV deficiency sco2 DISORDERED STEROIDOGENESIS POR CONGENITAL ADRENAL HYPERPLASIA CYP11B1 DONNAI-BARROW SYNDROME LRP2 CONGENITAL ADRENAL HYPERPLASIA CYP17A1 DONOHUE SYNDROME INSR CONGENITAL ADRENAL HYPOPLASIA NR0B1 DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE HSPG2 CONGENITAL DEAFNESS WITH KERATOPACHYDERMIA & CONSTRICTIONS GJB2 OF FINGERS & TOES ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY IKBKG CONGENITAL DISORDER OF GLYCOSYLATIO, TYPE IIa MGAT2 ECTODERMAL DYSPLASIA, HYPOHIDROTIC, X-LINKED EDA CONGENITAL DISORDER OF GLYCOSYLATION TYPE Ia PMM2 ELEJALDE DISEASE MYO5A CONGENITAL DISORDER OF GLYCOSYLATION TYPE Ic ALG6 ELLIS-VAN CREVELD SYNDROME EVC2 CONGENITAL DISORDER OF GLYCOSYLATION TYPE Ig ALG12 ELLIS-VAN CREVELD SYNDROME; EVC EVC CONGENITAL DISORDER OF GLYCOSYLATION TYPE Ii ALG2 ENCEPHALOPATHY, ETHYLMALONIC ETHE1 CONGENITAL DISORDER OF GLYCOSYLATION TYPE IIb MOGS EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE COL7A1 CONGENITAL DISORDER OF GLYCOSYLATION TYPE IIc SLC35C1 EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA ITGA6 CONGENITAL DISORDER OF GLYCOSYLATION TYPE IId B4GALT1 EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA ITGB4 CONGENITAL DISORDER OF GLYCOSYLATION TYPE Iig COG1 EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY PLEC1 CONGENITAL DISORDER OF GLYCOSYLATION TYPE Iih COG8 EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE LAMA3 CONGENITAL DISORDER OF GLYCOSYLATION TYPE Im DOLK EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE LAMB3 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib MPI EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE LAMC2 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; ALG3 EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE COL17A1 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie DPM1 EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE ITGB4 Diseases Tested – Preconception Genetic Carrier Screen DISEASE CODE DISEASE CODE EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE LAMA3 HEMOPHILIA A; HEMA F8 EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE LAMB3 HEMOPHILIA B; HEMB F9 EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE LAMC2 HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY VODI SP110
Load more

Recommended publications
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions Christopher C
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions Christopher C. Porter1, Todd E. Druley2, Ayelet Erez3, Roland P. Kuiper4, Kenan Onel5, Joshua D. Schiffman6, Kami Wolfe Schneider7, Sarah R. Scollon8, Hamish S. Scott9, Louise C. Strong10, Michael F. Walsh11, and Kim E. Nichols12 Abstract Leukemia, the most common childhood cancer, has long been patients. The panel recognized that for several conditions, recognized to occasionally run in families. The first clues about routine monitoring with complete blood counts and bone the genetic mechanisms underlying familial leukemia emerged marrow evaluations is essential to identify disease evolution in 1990 when Li-Fraumeni syndrome was linked to TP53 muta- and enable early intervention with allogeneic hematopoietic tions. Since this discovery, many other genes associated with stem cell transplantation. However, for others, less intensive hereditary predisposition to leukemia have been identified. surveillance may be considered. Because few reports describ- Although several of these disorders also predispose individuals ing the efficacy of surveillance exist, the recommendations to solid tumors, certain conditions exist in which individuals are derived by this panel are based on opinion, and local expe- specifically at increased risk to develop myelodysplastic syn- rience and will need to be revised over time. The development drome (MDS) and/or acute leukemia. The increasing identifica- of registries and clinical trials is urgently needed to enhance tion of affected individuals and families has raised questions understanding of the natural history of the leukemia-predis- around the efficacy, timing, and optimal methods of surveil- posing conditions, such that these surveillance recommenda- lance.
    [Show full text]
  • The Counsyl Foresight™ Carrier Screen
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • New Microdeletion and Microduplication Syndromes: a Comprehensive Review
    Genetics and Molecular Biology, 37, 1 (suppl), 210-219 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article New microdeletion and microduplication syndromes: A comprehensive review Julián Nevado1,2*, Rafaella Mergener3*, María Palomares-Bralo1,2, Karen Regina Souza3, Elena Vallespín1,2, Rocío Mena1,2, Víctor Martínez-Glez1,2, María Ángeles Mori1,2, Fernando Santos1,4, Sixto García-Miñaur1,4, Fé García-Santiago1,5, Elena Mansilla1,5, Luis Fernández1,6, María Luisa de Torres1,5, Mariluce Riegel3,7$ and Pablo Lapunzina1,4,8$ 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Section of Functional and Structural Genomics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre,RS, Brazil. 4Section of Clinical Genetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 5Section of Cytogenetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 6Section of Preanalytics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 7Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre ,RS, Brazil. 8Section of Molecular Endocrinology, Overgrowth Disordes Laboratory, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. Abstract Several new microdeletion and microduplication syndromes are emerging as disorders that have been proven to cause multisystem pathologies frequently associated with intellectual disability (ID), multiple congenital anomalies (MCA), autistic spectrum disorders (ASD) and other phenotypic findings. In this paper, we review the “new” and emergent microdeletion and microduplication syndromes that have been described and recognized in recent years with the aim of summarizing their main characteristics and chromosomal regions involved.
    [Show full text]
  • Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory
    The American Journal of Human Genetics, Volume 102 Supplemental Data Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory Sumit Punj, Yassmine Akkari, Jennifer Huang, Fei Yang, Allison Creason, Christine Pak, Amiee Potter, Michael O. Dorschner, Deborah A. Nickerson, Peggy D. Robertson, Gail P. Jarvik, Laura M. Amendola, Jennifer Schleit, Dana Kostiner Simpson, Alan F. Rope, Jacob Reiss, Tia Kauffman, Marian J. Gilmore, Patricia Himes, Benjamin Wilfond, Katrina A.B. Goddard, and C. Sue Richards Supplemental Note: Clinical Report Carrier Results: Four Known Pathogenic Variants Detected. Gene Inheritance Disease Prevalence Variant Classification Pendred Syndrome/ Non- syndromic Autosomal Hearing Loss A c.1246A>C, SLC26A4 1/500 Pathogenic Recessive DFNB4 with (p.Thr416Pro) enlarged vestibular aqueduct Autosomal Spastic ++ c.1045G>A, SPG7 2-6/100,000 Pathogenic Recessive Paraplegia 7 (p.Gly349Ser) 3.7 Autosomal Alpha +++ -α HBA2 1-5/10,000 Pathogenic Recessive Thalassemia (α+- thalassemia) Autosomal Hereditary 1/200 – c.845G>A HFE Pathogenic Recessive Hemochromatosis 1/1000+ (p.Cys282Tyr) +: GeneReviews; ++: Genetics Home Reference; +++: orphan.net – varies with population; A- Generalized prevalence of all deafness and hearing loss Interpretation: A sample from this individual was referred to our laboratory for analysis of Next-Generation Genome Sequencing (NGS) and Sanger confirmation of variants identified in carrier screening for: (1) conditions with significantly shortened lifespan; (2) serious conditions; (3) mild conditions; (4) conditions with unpredictable outcomes: and (5) conditions that begin as adults. One known heterozygous missense variant, c.1246A>C (p.Thr416Pro) (NM_000441.1), was detected in exon 10 of the SLC26A4 gene of this individual by NGS.
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • My Beloved Neutrophil Dr Boxer 2014 Neutropenia Family Conference
    The Beloved Neutrophil: Its Function in Health and Disease Stem Cell Multipotent Progenitor Myeloid Lymphoid CMP IL-3, SCF, GM-CSF CLP Committed Progenitor MEP GMP GM-CSF, IL-3, SCF EPO TPO G-CSF M-CSF IL-5 IL-3 SCF RBC Platelet Neutrophil Monocyte/ Basophil B-cells Macrophage Eosinophil T-Cells Mast cell NK cells Mature Cell Dendritic cells PRODUCTION AND KINETICS OF NEUTROPHILS CELLS % CELLS TIME Bone Marrow: Myeloblast 1 7 - 9 Mitotic Promyelocyte 4 Days Myelocyte 16 Maturation/ Metamyelocyte 22 3 – 7 Storage Band 30 Days Seg 21 Vascular: Peripheral Blood Seg 2 6 – 12 hours 3 Marginating Pool Apoptosis and ? Tissue clearance by 0 – 3 macrophages days PHAGOCYTOSIS 1. Mobilization 2. Chemotaxis 3. Recognition (Opsonization) 4. Ingestion 5. Degranulation 6. Peroxidation 7. Killing and Digestion 8. Net formation Adhesion: β 2 Integrins ▪ Heterodimer of a and b chain ▪ Tight adhesion, migration, ingestion, co- stimulation of other PMN responses LFA-1 Mac-1 (CR3) p150,95 a2b2 a CD11a CD11b CD11c CD11d b CD18 CD18 CD18 CD18 Cells All PMN, Dendritic Mac, mono, leukocytes mono/mac, PMN, T cell LGL Ligands ICAMs ICAM-1 C3bi, ICAM-3, C3bi other other Fibrinogen other GRANULOCYTE CHEMOATTRACTANTS Chemoattractants Source Activators Lipids PAF Neutrophils C5a, LPS, FMLP Endothelium LTB4 Neutrophils FMLP, C5a, LPS Chemokines (a) IL-8 Monocytes, endothelium LPS, IL-1, TNF, IL-3 other cells Gro a, b, g Monocytes, endothelium IL-1, TNF other cells NAP-2 Activated platelets Platelet activation Others FMLP Bacteria C5a Activation of complement Other Important Receptors on PMNs ñ Pattern recognition receptors – Detect microbes - Toll receptor family - Mannose receptor - bGlucan receptor – fungal cell walls ñ Cytokine receptors – enhance PMN function - G-CSF, GM-CSF - TNF Receptor ñ Opsonin receptors – trigger phagocytosis - FcgRI, II, III - Complement receptors – ñ Mac1/CR3 (CD11b/CD18) – C3bi ñ CR-1 – C3b, C4b, C3bi, C1q, Mannose binding protein From JG Hirsch, J Exp Med 116:827, 1962, with permission.
    [Show full text]
  • Molecular Characterization and Structural Implications of 25 New ABCB4 Mutations in Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3)
    European Journal of Human Genetics (2007) 15, 1230–1238 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3) Dario Degiorgio1, Carla Colombo2, Manuela Seia1, Luigi Porcaro1, Lucy Costantino1, Laura Zazzeron2, Domenico Bordo3 and Domenico A Coviello*,1 1Laboratorio di Genetica Medica, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy; 2Centro Fibrosi Cistica, Universita` degli Studi di Milano, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy; 3Bioinformatica e Proteomica Strutturale, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal-recessive disorder due to mutations in the ATP-binding cassette, subfamily B, member 4 gene (ABCB4). ABCB4 is the liver-specific membrane transporter of phosphatidylcholine, a major and exclusive component of mammalian bile. The disease is characterized by early onset of cholestasis with high serum c-glutamyltranspeptidase activity, which progresses into cirrhosis and liver failure before adulthood. Presently, about 20 distinct ABCB4 mutations associated to PFIC3 have been described. We report the molecular characterization of 68 PFIC3 index cases enrolled in a multicenter study, which represents the largest cohort of PFIC3 patients screened for ABCB4 mutations to date. We observed 31 mutated ABCB4 alleles in 18 index cases with 29 distinct mutations, 25 of which are novel. Despite the lack of structural information on the ABCB4 protein, the elucidation of the three-dimensional structure of bacterial homolog allows the three-dimensional model of ABCB4 to be built by homology modeling and the position of the mutated amino-acids in the protein tertiary structure to be located.
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]